Rie Sugimoto

3.3k total citations
49 papers, 1.5k citations indexed

About

Rie Sugimoto is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Rie Sugimoto has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hepatology, 17 papers in Epidemiology and 13 papers in Molecular Biology. Recurrent topics in Rie Sugimoto's work include Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Liver physiology and pathology (11 papers) and Liver Disease Diagnosis and Treatment (11 papers). Rie Sugimoto is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (12 papers), Liver physiology and pathology (11 papers) and Liver Disease Diagnosis and Treatment (11 papers). Rie Sugimoto collaborates with scholars based in Japan, United States and Italy. Rie Sugimoto's co-authors include Munechika Enjoji, Makoto Nakamuta, Hiroaki Iwamoto, Hajime Nawata, Seiya Tada, Naotaka Hamasaki, Mina Akaiwa, Kazuhiro Kotoh, Kenji Izuhara and Yoshiaki Yae and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rie Sugimoto

46 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rie Sugimoto Japan	22	428	423	417	399	214	49	1.5k
Gülsüm Özlem Elpek Türkiye	18	469 1.1×	244 0.6×	343 0.8×	437 1.1×	373 1.7×	94	1.5k
So Yeon Kim South Korea	19	637 1.5×	304 0.7×	279 0.7×	562 1.4×	178 0.8×	34	1.6k
Hyuk Soo Eun South Korea	20	460 1.1×	282 0.7×	278 0.7×	420 1.1×	161 0.8×	68	1.3k
Karlin Raja Karlmark Germany	10	393 0.9×	572 1.4×	783 1.9×	896 2.2×	253 1.2×	13	1.8k
Adrian Keogh Switzerland	26	701 1.6×	221 0.5×	565 1.4×	532 1.3×	328 1.5×	55	1.8k
Toshiaki Nakano Japan	23	566 1.3×	451 1.1×	398 1.0×	505 1.3×	401 1.9×	132	2.2k
Valeska Terpstra Netherlands	18	525 1.2×	588 1.4×	534 1.3×	534 1.3×	569 2.7×	32	2.1k
Kiyohiro Higuchi Japan	18	269 0.6×	279 0.7×	620 1.5×	557 1.4×	244 1.1×	34	1.4k
Sergio Duarte United States	16	436 1.0×	188 0.4×	389 0.9×	294 0.7×	284 1.3×	40	1.2k
A. Katrina Loomis United States	16	357 0.8×	800 1.9×	341 0.8×	878 2.2×	150 0.7×	19	2.0k

Countries citing papers authored by Rie Sugimoto

Since Specialization

Citations

This map shows the geographic impact of Rie Sugimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rie Sugimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rie Sugimoto more than expected).

Fields of papers citing papers by Rie Sugimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rie Sugimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rie Sugimoto. The network helps show where Rie Sugimoto may publish in the future.

Co-authorship network of co-authors of Rie Sugimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Rie Sugimoto. A scholar is included among the top collaborators of Rie Sugimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rie Sugimoto. Rie Sugimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ogawa, Eiichi, Motoyuki Kohjima, Toshimasa Koyanagi, et al.. (2025). Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment. Journal of Gastroenterology and Hepatology. 40(10). 2560–2567.

Naganuma, Atsushi, Fujio Makita, Rie Sugimoto, et al.. (2024). An open-label, randomized, controlled trial on the benefit of β-hydroxy-β-methyl butyrate, l-arginine, l-glutamine combination beverages and locomotion training as supportive care for the treatment of unresectable hepatocellular carcinoma using lenvatinib: A pilot study (HELLO study). Clinical Nutrition ESPEN. 65. 357–364. 1 indexed citations

Sugimoto, Rie, et al.. (2023). Zinc Deficiency as a General Feature of Cancer: a Review of the Literature. Biological Trace Element Research. 202(5). 1937–1947. 23 indexed citations

Imaoka, Hiroshi, Masafumi Ikeda, Shogo Nomura, et al.. (2023). Development of a nomogram to predict survival in advanced biliary tract cancer. Scientific Reports. 13(1). 21548–21548. 1 indexed citations

Sugimoto, Rie, Akira Nakanishi, Lingaku Lee, et al.. (2021). Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma. Clinical Journal of Gastroenterology. 14(5). 1484–1490. 4 indexed citations

Sugimachi, K, Yohei Mano, Yoshihiro Matsumoto, et al.. (2021). Adenomyomatous hyperplasia of the extrahepatic bile duct: a systematic review of a rare lesion mimicking bile duct carcinoma. Clinical Journal of Gastroenterology. 14(2). 393–401. 5 indexed citations

Sugimoto, Rie, Masayuki Furukawa, Mototsugu Shimokawa, et al.. (2020). Risk factors for de novo hepatitis B during solid cancer treatment. World Journal of Clinical Cases. 8(24). 6264–6273. 3 indexed citations

Ikeda, M., Satoshi Shimizu, Tosiya Sato, et al.. (2016). Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Annals of Oncology. 27(11). 2090–2096. 110 indexed citations

Fukushima, Marie, Munechika Enjoji, Motoyuki Kohjima, et al.. (2005). Adipose differentiation related protein induces lipid accumulation and lipid droplet formation in hepatic stellate cells. In Vitro Cellular & Developmental Biology - Animal. 41(10). 321–324. 41 indexed citations

10.

Fukushima, Marie, Munechika Enjoji, Motoyuki Kohjima, et al.. (2005). ADIPOSE DIFFERENTIATION RELATED PROTEIN INDUCES LIPID ACCUMULATION AND LIPID DROPLET FORMATION IN HEPATIC STELLATE CELLS. In Vitro Cellular & Developmental Biology - Animal. 41(10). 321–321. 1 indexed citations

11.

Nakamuta, Makoto, Munechika Enjoji, Satoshi Ohta, et al.. (2002). BISPHENOL A DIGLYCIDYL ETHER (BADGE) SUPPRESSES TUMOR NECROSIS FACTOR‐α PRODUCTION AS A PPARγ AGONIST IN THE MURINE MACROPHAGE‐LIKE CELL LINE, RAW 264.7. Cell Biology International. 26(3). 235–241. 30 indexed citations

12.

Enjoji, Munechika, Manabu Nakashima, Hidehiro Nishi, et al.. (2002). The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract. Journal of Hepatology. 36(6). 786–792. 31 indexed citations

13.

Nakamuta, Makoto, Satoshi Ohta, Seiya Tada, et al.. (2001). Dimethyl sulfoxide inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. International Journal of Molecular Medicine. 8(5). 553–60. 28 indexed citations

14.

Enjoji, Munechika, et al.. (2001). Activation of Retinoic X Receptor and Peroxisome Proliferator-Activated Receptor–γ Inhibits Nitric Oxide and Tumor Necrosis Factor–α Production in Rat Kupffer Cells. Hepatology. 33(1). 91–99. 112 indexed citations

15.

Tada, Seiya, Munechika Enjoji, Rie Sugimoto, et al.. (2001). Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In Rats. Clinical and Experimental Pharmacology and Physiology. 28(7). 522–527. 71 indexed citations

16.

Suyama, Ritsuko, Rie Sugimoto, Mina Akaiwa, et al.. (2000). Characterization of IL-4 and IL-13 signals dependent on the human IL-13 receptor α chain 1: redundancy of requirement of tyrosine residue for STAT3 activation. International Immunology. 12(11). 1499–1509. 58 indexed citations

17.

Iwamoto, Hiroaki, Makoto Nakamuta, Seiya Tada, et al.. (2000). A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. Journal of Hepatology. 32(5). 762–770. 89 indexed citations

18.

Iwamoto, Hiroaki, et al.. (2000). Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth. Journal of Laboratory and Clinical Medicine. 135(5). 406–412. 28 indexed citations

19.

Arinobu, Yojiro, Rie Sugimoto, Mina Akaiwa, et al.. (2000). Augmentation of Signal Transducer and Activation of Transcription (STAT)6 and STAT3 Expression in Stimulated B and T Cells. Biochemical and Biophysical Research Communications. 277(2). 317–324. 9 indexed citations

20.

Sugimoto, Rie, Yoshiaki Yae, Mina Akaiwa, et al.. (1998). Cloning and Characterization of the Hakata Antigen, a Member of the Ficolin/Opsonin p35 Lectin Family. Journal of Biological Chemistry. 273(33). 20721–20727. 186 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact